Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Medical imaging
3. Definitions
4. SPECT/CT - the simple principle
5. Hybrid SPECT/CT - the best of both worlds
6. History of SPECT/CT (1999-2009)
7. SPECT/CT: classic clinical applications
8. Sources of error in SPECT/CT imaging
9. Display errors
10. Misregistration in cardiac SPECT/CT
11. SPECT/CT referral criteria: clinical data
12. Data from previous anatomic imaging
13. (Planar) nuclear medicine data
14. Discovering new patterns and pitfalls
15. Patterns unrelated to disease
16. Devices: SPECT/low-doseCT - GE Hawkeye 4
17. Devices: SPECT/multi-sliceCT - Siemens Symbia
18. SPECT/multi-sliceCT - Phillips Precedence
19. Dedicated cardiac solid-state CZT SPECT/64CT
20. Clinical SPECT/CT devices on the market today
21. Nuclear medicine procedures: pros and cons
22. SPECT and CT - complementary role in imaging
23. Clinical indications for SPECT/CT
24. Endocrine tumors
25. In-111-octreotide SPECT/CT in NET
26. SPECT/CT: pancreatic insulinoma
27. In-111-octreotide SPECT/CT in NET: literature data
28. I-123-MIBG SPECT/CT in neural crest tumors
29. I-123-MIGB SPECT/CT: pheochromocytoma
30. I-123-MIBG SPECT/CT in neuroblastoma
31. I-123-MIBG SPECT: metastatic neuroblastoma
32. I-123-MIBG SPECT/CT: localization of metastases
33. I-131 SPECT/CT in thyroid cancer (1)
34. I-131 SPECT/CT in thyroid cancer (2)
35. I-131 SPECT/CT: tracer uptake, nodal metastases
36. I-131 SPECT/CT: differentiated thyroid cancer
37. I-131 SPECT/CT in thyroid cancer - summary
38. Tc-99m-MIBI SPECT/CT of parathyroid adenoma
39. Importance of pre-operative localization of PTA
40. Tc-99m-MIBI SPECT/CT: Rt. PTA
41. SPECT/CT: diagnosis and localization of Rt. PTA
42. Tc-99m-MIBI SPECT/CT imaging of PTA
43. SPECT/CT in sentinel node mapping
44. "Sentinel node" concept and lymphoscintigraphy
45. SPECT/CT lymphoscintigraphy: breast cancer
46. Lymphoscintigraphy: malignant melanoma
47. Planar lymphoscintigraphy: breast cancer
48. Benefit of combined SPECT-lymphoscintigraphy
49. SPECT/CT: localization of internal mammary SLN
50. Bone SPECT/CT
51. Bone SPECT/CT in cancer patients
52. Bone SPECT/CT: breast cancer, staging
53. Bone SPECT/CT: lung cancer, staging
54. Bone SPECT/CT: colon cancer, pelvic pain
55. Tc-MDP SPECT/CT improves scan specificity
56. SPECT/CT in infection
57. SPECT in infection: indications and radiotracers
58. SPECT/CT in musculo-skeletal infections
59. SPECT/CT: susp. vertebral osteomyelitis (1)
60. SPECT/CT: susp. vertebral osteomyelitis (2)
61. WBC SPECT/CT for bone and joint infection
62. Infection of the chest and abdomen
63. SPECT/CT: susp. NHL recurrence
64. SPECT/CT: mediastinal Hodgkin
65. Ga-67 and WBC SPECT/CT in infection
66. SPECT/CT in nuclear cardiology
67. CT-based attenuation correction
68. Attenuation correction of diaphragm artefact
69. SPECT/CT: lateral wall ischemia
70. Integrated SPECT/CTCA diagnosis
71. Cardiac SPECT/64-CT: abnormal perfusion
72. Cardiac SPECT/64-CT: multiple CT abnormalities
73. SPECT/64-CT: apical ischemia supplied by LAD
74. Benefit of combined SPECT/CTCA
75. Suggested SPECT/CT protocols
76. SPECT/CT and negative scintigraphy?
77. SPECT/CT in infection/ inflammation: future goals
78. "Evolution for bone"
79. "Half-time" evolution bone SPECT/CT
80. Multi-FOV bone SPECT/CT acquisition
81. The promising role of SPECT/CT (1)
82. The promising role of SPECT/CT (2)
83. SPECT/CT is becoming a must-have technology
84. Elements of danger - the case of medical imaging
85. Thank you

Topics Covered

• History of SPECT/CT
• Pitfalls and sources of errors in SPECT/CT imaging
• Referral criteria to SPECT/CT
• Clinical SPECT/CT devices
• Clinical indications for SPECT/CT: endocrine disease
• Neuroendocrine tumors, thyroid cancer, parathyroid adenoma, lymphoscintigraphy, bone imaging in cancer patients, infection and nuclear cardiology
• Clinical protocols for SPECT/CT
• SPECT/CT: future goals

Links

Series:

• Medical Imaging

Categories:

• Clinical Practice
• Methods

Talk Citation

Publication History

• Published on April 1, 2010

Financial Disclosures

• Prof. Ora Israel has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.